ReviewEffects of diabetes drugs on the skeleton
Introduction
Type 2 diabetes is associated with increased fracture risk despite the fact that patients with diabetes have higher bone mineral density as compared to non-diabetic individuals [1], [2], [3]. The mechanisms underlying the detrimental effects of diabetes on skeletal health are only partially understood. It is assumed that determinants of fracture risk are multifactorial including diabetes-related microvascular complications, fall risk and alterations associated with chronic hyperglycemia [4]. As documented in preclinical models hyperglycemia may alter calcium and vitamin D metabolism resulting in impaired bone mineralization [5], [6]. Furthermore, chronic hyperglycemia may result in deposition of advanced glycosylation end-products in bone collagen (such as pentosidine) contributing to impaired bone quality [7], [8] and higher fracture risk [9], [10]. Several studies suggest that skeletal dynamics are reduced in type 2 diabetes [4] with decreased osteoblast function as documented by reduced biochemical markers of bone formation [11] and lower bone formation rate in a histomorphometric study [12]. Several pathophysiological changes in diabetics might contribute to decreased bone formation. They include interference of advanced glycosylation end-products with osteoblast development [13], function [14] and attachment to collagen matrix [15], increased levels of osteocyte-derived sclerostin [16], [17], [18], and hyperglycemia-induced suppression of osteogenic differentiation of marrow-derived progenitor cells diverting osteoblastic precursor cells to a metabolically stressed adipogenic pathway that induces synthesis of a hyaluronan matrix that recruits inflammatory cells and establishes an inflammatory process contributing to bone demineralization [19].
Antidiabetic drugs are indispensable for glycemic control in most type 2 diabetics. However before discussing potential benefits or risks of antidiabetic drugs on bone metabolism it seems evident that optimal glycemic control per se is an important contributing factor for improvement of skeletal integrity in diabetic patients. This notion is supported by several studies showing increased fracture risk in patients with poor glycemic control and reduced risk in patients on intensive glycemic control.
A recent cohort study explored the association between glycemic control as measured by serum hemoglobin A1c (HbA1c) levels and the risk of hip fracture in type 2 diabetics aged over 65 years and observed a linear relationship between HbA1c and hip fracture risk. After adjustment for various contributing factors hip fracture risk was 24–31% higher among diabetics with HbA1c levels above 9% than among patients with HbA1c levels of 6–7% [20]. These data are in line with some but not all previous studies confirming a detrimental effect of poor glycemic control on fracture risk [21], [22], [23]. In contrast, however, this relationship could not be observed in the ACCORD trial, a clinical trial investigating type 2 diabetics randomized either to intensive or standard treatment strategies. The lack of significant effect of glycemic control on the occurrence of non-vertebral fractures (and falls) might be attributed to the small difference in effective diabetes control between patients with intensified treatment strategy (HbA1c 6.4%) and standard treatment (HbA1c 7.5%) [24]. Although reducing hyperglycemia is mandatory not only for skeletal health but also in decreasing the onset and progression of microvascular complications, individualized treatment is necessary, balancing the benefits and risks of glycemic control based on the patient's age and health status [25]. Drug-induced hypoglycemic episodes need to be avoided which in addition to diabetic complications (neuropathy, retinopathy) may increase the risk of falls and fractures.
This review summarizes the effects of antidiabetic drugs on bone metabolism and fracture risk (Table 1). Preclinical and clinical data of both, insulin sensitizers (metformin, thiazolidinediones) and insulin secretagogues are discussed with specific focus on the skeletal effects of recently marketed drugs such as incretin-based therapies (GLP-1 receptor agonists, DPP-4 inhibitors) and SGLT2-inhibitors.
Section snippets
Metformin
Metformin is most commonly used to increase insulin sensitivity in diabetic patients. Biguanides decrease hepatic glucose production and increase glucose uptake in muscle. Metformin is considered by the World Health Organization an essential medicine satisfying the criteria of the public health relevance, evidence on efficacy and safety, and comparative cost effectiveness (www.who.int/medicines). Metformin mechanism of insulin sensitization includes activation of hepatic and muscle
Thiazolidinediones
TZDs increase insulin sensitivity via activation of peroxisome proliferator-activated receptor (PPARγ). Two TZDs, rosiglitazone and pioglitazone, have been used clinically since 1999. A number of studies showed superior efficacy of TZDs over other available antidiabetic therapies in the control of diabetic hyperglycemia [41]. However, their prolonged use is associated with several adverse effects. Strong clinical evidence points to the connection between rosiglitazone use and a significant
Sulfonylureas
Although sulfonylureas are widely used for many years in type 2 diabetics, data on their skeletal safety are scarce. Nevertheless, based on epidemiological studies with adjustments for covariables, sulfonylureas seem to have a beneficial effect on fracture risk irrespective of the duration of treatment [34], [89]. Evidence from both the ADOPT studies and the Rochester studies indicates that glibenclamide (glyburide) therapy does not have an effect on bone mass and fracture risk [32], [41].
Incretin-based therapies
Nearly 10 years ago glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have been approved for the treatment of type 2 diabetes and are widely used as second-line agents in case of inadequate glycemic control [25].
Incretins are gut-derived hormones which exert their actions through activation of incretin receptor signaling. Glucagon-like peptides (GLP-1, GLP-2) and glucose-dependent insulinotropic polypeptide (GIP) are related hormones released from intestinal
SGLT-2 inhibitors
Recently, a new class of glucose-lowering agents, the sodium-glucose co-transporter 2 (SGLT2) inhibitors have become available [25], [120]. Sodium-glucose co-transporters are responsible for renal glucose reabsorption with SGLT2 accounting for approximately 90% of reabsorbed glucose. SGLT2 actively transports glucose across the proximal nephron, an action which is independent of insulin [121]. Inhibition of SGLT2 results in increasing urinary excretion of glucose, thereby decreasing serum HbA1c
References (128)
- et al.
Glucose-induced inhibition of in vitro bone mineralization
Bone
(2001) - et al.
Influence of nonenzymatic glycation on biomechanical properties of cortical bone
Bone
(2001) - et al.
Advanced glycation endproducts interefere with integrin-mediated osteoblastic attachment to a type-I collagen matrix
Int J Biochem Cell Biol
(2004) - et al.
Hyperglycemia diverts dividing osteoblastic precursor cells to an adipogenic pathway and induces synthesis of a hyaluronan matrix that is adhesive for monocytes
J Biol Chem
(2014) - et al.
Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2
Bone
(2011) - et al.
Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats
Eur J Pharmacol
(2011) - et al.
Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials
Bone
(2014) - et al.
PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss
Cell Metab
(2010) - et al.
Protein phosphatase 5 mediates lipid metabolism through reciprocal control of glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma (PPARgamma)
J Biol Chem
(2011) - et al.
Pharmacology, physiology, and mechanisms of incretin hormone action
Cell Metab
(2013)
Biology of incretins: GLP-1 and GIP
Gastroenterology
Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women
Bone
Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis
Osteoporos Int
Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture
Am J Epidemiol
Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes
JAMA
Type 2 diabetes and bone
J Bone Miner Res
Bone mineral homeostasis in spontaneously diabetic BB rats. I. Abnormal vitamin D metabolism and impaired active intestinal calcium absorption
Endocrinology
Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats
Osteoporos Int
Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes
Diabetes Care
Pentosidine and increased fracture risk in older adults with type 2 diabetes
J Clin Endocrinol Metab
Biochemical bone turnover markers in diabetes mellitus—a systematic review
Bone
Bone loss and bone turnover in diabetes
Diabetes
Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone
J Bone Miner Res
Pentosidine effects on human osteoblasts in vitro
Ann N Y Acad Sci
Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes
J Clin Endocrinol Metab
Sclerostin levels associated with inhibition of the Wnt/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus
J Clin Endocrinol Metab
Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures
Osteoporos Int
Glycated hemoglobin level and risk of hip fracture in older people with type 2 diabetes: a competing risk analysis of Taiwan Diabetes Cohort Study
J Bone Miner Res
Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women
Diabetes Care
High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study
Diabetes Care
Diabetes and risk of fracture-related hospitalization: the Atherosclerosis Risk in Communities Study
Diabetes Care
Intensive glycemic control and thiazolidinedione use: effects on cortical and trabecular bone at the radius and tibia
Calcif Tissue Int
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
Diabetes Care
Role of AMP-activated protein kinase in mechanism of metformin action
J Clin Invest
Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats
J Cell Biochem
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from a Diabetes Outcome Progression Trial (ADOPT)
Diabetes Care
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes
J Clin Endocrinol Metab
Fracture risk in type 2 diabetes: update of a population-based study
J Bone Miner Res
Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes
Calcif Tissue Int
Use of thiazolidinediones and fracture risk
Arch Intern Med
Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case–control study
Diabetes Care
Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus
J Bone Miner Metab
Thiazolidinediones and fractures: evidence from translating research into action for diabetes
J Clin Endocrinol Metab
Scottish Diabetes Research Network Epidemiology G. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs
Diabetologia
Fracture risk in diabetic elderly men: the MrOS study
Diabetologia
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
BMJ
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
N Engl J Med
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
N Engl J Med
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials
JAMA
Thiazolidinediones
N Engl J Med
Cited by (125)
Use of sodium-glucose co-transporter 2 inhibitors, changes in body mass index and risk of fracture: A population-based cohort study
2022, Diabetes Research and Clinical PracticeCitation Excerpt :To some extent, this is in line with the meta-analysis by Cheng et al [5], in which a beneficial effect on the risk of fractures was found in users of SGLT-2 inhibitors, but this beneficial effect disappeared when the treatment period was longer than one year. Potentially, a longer duration of SGLT-2 inhibitor use increases the risk of major osteoporotic fractures by altered calcium/phosphate homeostasis [30–32]. The results of the current study suggest an increased risk of fracture after SGLT-2 inhibitor use for at least 630 DDDs, which could correspond to approximately 1.7 years of continuous use (630/365 days).
Effect of pharmacological treatment prior to admission on the outcome of older hip fracture patients
2021, Archives of Gerontology and GeriatricsCitation Excerpt :Many factors have been related to the risk of suffering a hip fracture (Scottish Intercollegiate Guidelines Network (SIGN), 2015), among them, different types of drugs have been individually associated with increased fracture risk. Some studies have related the drug with an increased risk of falling, the so-called FRIDS (falling risk increasing drugs) (van der Velde, Stricker, Pols & van der Cammen, 2007), but also some studies showed a negative effect of the drug on bone metabolism, which would increase it frailty (Compston, 2018; Meier, Schwartz, Egger & Lecka-Czernik, 2016). Moreover, pharmacological treatment could be an indirect indicator of the patient's morbidity.
Age- and obesity-related metabolic changes and their impact on the incidence of digestion, metabolism, and immune health
2021, Nutrition and Functional Foods in Boosting Digestion, Metabolism and Immune Health